To the full analysis
Buyback calculator for Jiangsu Hengrui Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals stock: key metrics
1276.HKJiangsu Hengrui Pharmaceuticals had an operating margin of 28.4% and a return on invested capital (ROIC) of 38.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 80.5% | 18.9% | 14.4% |
| 2007 | 83.3% | 18.5% | 20.9% |
| 2008 | 83.2% | 25.7% | 17.7% |
| 2009 | 82.7% | 22.7% | 22.0% |
| 2010 | 83.8% | 22.3% | 19.3% |
| 2011 | 81.9% | 22.7% | 19.6% |
| 2012 | 83.1% | 24.0% | 20.2% |
| 2013 | 81.0% | 23.4% | 20.3% |
| 2014 | 81.5% | 23.1% | 20.7% |
| 2015 | 84.5% | 26.3% | 23.7% |
| 2016 | 86.4% | 26.4% | 23.7% |
| 2017 | 86.0% | 26.3% | 23.6% |
| 2018 | 85.3% | 23.6% | 23.6% |
| 2019 | 86.2% | 23.7% | 23.1% |
| 2020 | 87.1% | 22.7% | 23.0% |
| 2021 | 84.5% | 14.6% | 17.6% |
| 2022 | 83.6% | 19.3% | 18.4% |
| 2023 | 84.6% | 21.5% | 18.9% |
| 2024 | 86.2% | 26.8% | 22.6% |
| 2025 | 86.2% | 28.4% | 24.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 16.1% | 25.5% | 13.8% |
| 2007 | 24.3% | 36.2% | 19.2% |
| 2008 | 20.9% | 46.2% | 18.7% |
| 2009 | 25.5% | 34.6% | 22.2% |
| 2010 | 20.8% | 32.5% | 18.1% |
| 2011 | 20.3% | 30.0% | 17.7% |
| 2012 | 20.4% | 28.8% | 18.1% |
| 2013 | 19.2% | 28.8% | 16.9% |
| 2014 | 19.2% | 31.3% | 16.8% |
| 2015 | 22.6% | 41.5% | 19.5% |
| 2016 | 21.9% | 43.2% | 18.9% |
| 2017 | 20.1% | 44.0% | 17.1% |
| 2018 | 21.3% | 43.6% | 18.8% |
| 2019 | 21.8% | 45.7% | 19.6% |
| 2020 | 19.7% | 40.1% | 17.3% |
| 2021 | 12.8% | 22.2% | 11.4% |
| 2022 | 10.5% | 19.2% | 9.4% |
| 2023 | 10.7% | 20.8% | 9.9% |
| 2024 | 13.9% | 31.1% | 12.6% |
| 2025 | 12.6% | 38.9% | 11.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 29 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.